Cargando…

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions

Pancreatic cancer is one of the most lethal cancers, where curative surgical resections are rare and less than 5% of patients experience long-term survival. Despite numerous clinical trials, improvements in the systemic treatment of this disease have been limited. Gemcitabine, a nucleoside analogue,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spratlin, Jennifer L., Mackey, John R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840445/ https://www.ncbi.nlm.nih.gov/pubmed/24281217 http://dx.doi.org/10.3390/cancers2042044

Ejemplares similares

Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
por: Boyd, Lenka N. C., et al.
Publicado: (2023)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
por: Raffenne, Jerome, et al.
Publicado: (2019)

Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
por: Kim, Jaihwan, et al.
Publicado: (2018)

Gestational Diabetes—Placental Expression of Human Equilibrative Nucleoside Transporter 1 (hENT1): Is Delayed Villous Maturation an Adaptive Pattern?
por: Giacometti, Cinzia, et al.
Publicado: (2023)

A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine
por: Kalloger, Steve E, et al.
Publicado: (2017)

Bidirectional transport of 2-chloroadenosine by equilibrative nucleoside transporter 4 (hENT4): Evidence for allosteric kinetics at acidic pH
por: Tandio, David, et al.
Publicado: (2019)

Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?
por: Hwang, Dae Wook, et al.
Publicado: (2020)

Decreased erythrocyte nucleoside transport and hENT1 transporter expression in glucose 6-phosphate dehydrogenase deficiency
por: Al-Ansari, Mohammad, et al.
Publicado: (2015)

Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease
por: Guitart, Xavier, et al.
Publicado: (2017)

HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
por: Eltzschig, Holger K., et al.
Publicado: (2005)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1)
por: Boswell-Casteel, Rebba C., et al.
Publicado: (2018)

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
por: Elander, N. O., et al.
Publicado: (2018)

Equilibrative nucleoside transporter 1 (ENT1) is critical for pollen germination and vegetative growth in Arabidopsis
por: Bernard, Carsten, et al.
Publicado: (2011)

Changes in aortic reactivity associated with the loss of equilibrative nucleoside transporter 1 (ENT1) in mice
por: Best, K. Arielle, et al.
Publicado: (2018)

Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors
por: Jouan, Elodie, et al.
Publicado: (2021)

Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development
por: Deniskin, Roman, et al.
Publicado: (2015)

N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function
por: Bicket, Alex, et al.
Publicado: (2016)

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
por: Elebro, Jacob, et al.
Publicado: (2016)

hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
por: Wang, Wei, et al.
Publicado: (2023)

Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling
por: Ruan, Wei, et al.
Publicado: (2023)

Functional characterization of human equilibrative nucleoside transporter 1
por: Huang, Weiyun, et al.
Publicado: (2016)

Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1)
por: Logie, Lisa, et al.
Publicado: (2018)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo, Zhongyi, et al.
Publicado: (2018)

Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity Contributes to the High Extracellular Adenosine Levels in Mesenchymal Glioblastoma Stem-Like Cells
por: Alarcón, Sebastián, et al.
Publicado: (2020)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Insight into the nucleoside transport and inhibition of human ENT1
por: Wu, Zhixiang, et al.
Publicado: (2022)

Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes
por: Perrone, G., et al.
Publicado: (2010)

Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis.
por: Pressacco, J., et al.
Publicado: (1995)

Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles
por: Naes, Safaa M., et al.
Publicado: (2020)

Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
por: Xi, Yue, et al.
Publicado: (2022)

SKM-1细胞地西他滨耐药机制中hENT1功能的研究
Publicado: (2015)

Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters
por: Miller, Siennah R., et al.
Publicado: (2021)

Novel variants provide differential stabilisation of human equilibrative nucleoside transporter 1 states
por: Boakes, Jessica C., et al.
Publicado: (2022)

Human equilibrative nucleoside transporter‐1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S‐1 chemotherapy
por: Okamura, Yukiyasu, et al.
Publicado: (2019)

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
por: Eto, K, et al.
Publicado: (2013)

FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia
por: Català, Albert, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p58sl524r0vlc2g6shhalvvc37